NASDAQ · NTRBW

Nutriband Inc.

$0.53 +$0.03 (+6.00%) 1D

Key Metrics

$5.90M
Market cap
40.14×
P/E · TTM
−$234.03K
Revenue · TTM
$146.91K
Net income
EPS · TTM $0.01
Dividend yield
Free cash flow
Beta · 1Y
EBITDA · TTM
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 20
    From its Feb 5 high, the share price fell 70%.

    Peak close $1.65 on Feb 5; trough close $0.50 on Jul 20. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -70%
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 16
    The stock moved +34.4% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 16
  • May 4
    The stock moved +30.3% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 4

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap
Enterprise value
Shares outstanding
52-wk range$0.50 – $2.99
Avg volume · 20D14.0K
Net cash
Book value / share$0.54
IndustryOrthopedic, Prosthetic & Surgical Appliances & Supplies
ExchangeNASDAQ
About Nutriband Inc.
IPO dateOct 1, 2021
Employees3

Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E40.14
P/S
P/FCF
EV/EBITDA
EV/Sales
Graham №$0.40

Profitability

Gross
Operating -62.8%
Net -62.8%
FCF
ROE / ROIC 2.5% · —

Financial Health

Current ratio5.26
Quick ratio5.11
Debt / equity
Debt / EBITDA
Net cash
Working capital$3.54M

Cash Flow · TTM

Operating CF
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

0 / 9
Weak fundamentals · 0 of 9 signals passing

Altman Z-Score

-5.2
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

$0.40 vs $0.53
Trades 1.3× above classic defensive value — priced for growth
Fundamentals through 2026-04-30 · computed by TickerWolf from SEC filings